Skip to content

To evaluate the efficacy of NiKu plus as supplementation in type 2 diabetic patients

A randomised open label parallel group clinical study to evaluate the safety and efficacy of JRKs NiKu plus in reducing the blood sugar levels in type 2 diabetic patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/09/015647
Enrollment
24
Registered
2018-09-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E08-E13- Diabetes mellitus Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: NIKU PLUS: Andrographis paniculata -20% Zingiber officinale -10% Piper nigrum -10% Cyperus rotundus -10% Tinospora cordifolia -10% Adhatoda vasica -10% Syzygium cumini -10%

Sponsors

Dr JRKs Research and Pharmaceuticals Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Proper written informed consent obtained from the patient before any procedure is being performed. 2.Male or female Type 2 DM patients on oral hypoglycemic agents, in the age group of 18-45 years. 3.Patient should have not participated in any other clinical trial during the past 3 months.

Exclusion criteria

Exclusion criteria: 1.Patient who are unable to consume solid and liquid orals. 2.Patients who are having complications of Diabetes mellitus and suffering from other co morbid conditions. 3.Patients who are unable to sign informed consent. 4.Patient unwilling or unable to comply with study procedure.

Design outcomes

Primary

MeasureTime frame
Percentage Change in the blood sugar levels before and after interventionTimepoint: DAY 0 day 1 day 3 day 6 and Day 7

Secondary

MeasureTime frame
monitoring of adverse drug reactionsTimepoint: DAY 0 day 1 day 3 day 6 and Day 7

Countries

India

Contacts

Public ContactRamesh Kannan

MMC, Chennai

srkguruvarshan@gmail.com7708925866

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026